Head-To-Head Analysis: Oncobiologics (NASDAQ:OTLK) vs. Celldex Therapeutics (NASDAQ:CLDX)

Oncobiologics (NASDAQ:OTLK) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Oncobiologics and Celldex Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1	2	2	0	2.20
Celldex Therapeutics	1	1	11	0	2.77

Oncobiologics currently has a consensus target price of $5.20, indicating a potential upside of 981.08%. Celldex Therapeutics has a consensus target price of $64.08, indicating a potential upside of 112.55%. Given Oncobiologics’ higher possible upside, equities analysts plainly believe Oncobiologics is more favorable than Celldex Therapeutics.

Institutional & Insider Ownership

11.2% of Oncobiologics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Oncobiologics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Profitability

This table compares Oncobiologics and Celldex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Celldex Therapeutics	N/A	-52.66%	-47.58%

Valuation and Earnings

This table compares Oncobiologics and Celldex Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	-$1.16 million	-100.64	-$62.42 million	($0.77)	-0.62
Celldex Therapeutics	$158,000.00	14,991.42	-$258.76 million	($4.30)	-7.01

Oncobiologics has higher earnings, but lower revenue than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Summary

Celldex Therapeutics beats Oncobiologics on 7 of the 13 factors compared between the two stocks.

About Oncobiologics

Oncobiologics, now known as Outlook Therapeutics, Inc. (NASDAQ: OTLK), is a biopharmaceutical company focused on developing and commercializing ophthalmic therapies for retinal diseases. The company was established as Oncobiologics and later changed its name to Outlook Therapeutics to reflect its emphasis on eye-care products. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab designed for intravitreal use. The therapy has been studied for vascular retinal conditions, including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion.

About Celldex Therapeutics

Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based treatments for inflammatory diseases and cancer. Its research focuses on targets involved in immune responses and the activity of mast cells. The company’s lead candidate, barzolvolimab, is an antibody that targets the KIT receptor. Celldex is studying it for chronic urticaria and other conditions associated with mast-cell activity. Celldex also has early-stage oncology programs that investigate antibody therapies designed to affect immune pathways.